- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or recurrent glioblastoma; Advanced (unresectable) Barcelona Clinic Liver Cancer; Stage B or Stage C hepatocellular carcinoma; Stage IV (metastatic) non-small cell lung cancer (NSCLC); Advanced carcinoma of cervix; Advanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer; Metastatic colorectal cancer.
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 306KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 45KB)
Bevacizumab – November 2021
Bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Abevmy®
Last updated
4 March 2022